How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
RNA Drugs Market
- By Drug Type: mRNA Therapeutics, siRNA Therapeutics, Antisense Oligonucleotides (ASOs), miRNA Therapeutics, RNA Aptamers
- By Therapeutic Application: Oncology, Rare Genetic Disorders, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders
- By Delivery Technology: Lipid Nanoparticles (LNPs), Polymeric Nanoparticles, Conjugated Delivery Systems, Viral Vectors, Exosome-based Delivery
- By End User: Hospitals and Clinics, Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - mRNA Therapeutics leads By Drug Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.168 →
- 11 Company Profiles 17 players: SWOT & benchmarking p.176 →
Full report · locked preview
Everything inside the RNA Drugs Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Drug Type 5
Therapeutic Application 5
Delivery Technology 5
End User 4
Companies profiled
Moderna Inc.
BioNTech SE
Alnylam Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc.
CureVac N.V.
Arcturus Therapeutics Holdings Inc.
Dicerna Pharmaceuticals
Inc. (a subsidiary of Novo Nordisk)
Sarepta Therapeutics Inc.
Translate Bio
Inc. (acquired by Sanofi)
Akcea Therapeutics Inc.
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Moderna Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →BioNTech SE
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Alnylam Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Ionis Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →CureVac N.V.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Arcturus Therapeutics Holdings Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Dicerna Pharmaceuticals
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Inc. (a subsidiary of Novo Nordisk)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Sarepta Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Translate Bio
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Inc. (acquired by Sanofi)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Akcea Therapeutics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Wave Life Sciences Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Arrowhead Pharmaceuticals Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Silence Therapeutics plc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Patisiran (developed by Alnylam Pharmaceuticals)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Duke University (not a company but notable in RNA drug development)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$10,514M by 2033 · 9.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- mRNA Therapeutics45.3
- siRNA Therapeutics17.5
- Antisense Oligonucleotides (ASOs)15.4
- miRNA Therapeutics12.5
- RNA Aptamers9.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,727M → $3,544M · 9.4%
Europe$1,204M → $2,673M · 10.5%
Asia Pacific$1,099M → $2,412M · 10.3%
Latin America$680.3M → $1,479M · 10.2%
Middle East and Africa$523.3M → $972.7M · 8.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.062026
9.072027
9.092028
9.112029
9.112030
9.132031
9.142032
9.152033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Moderna Inc.20.4
- BioNTech SE14.5
- Alnylam Pharmaceuticals Inc.9.7
- Ionis Pharmaceuticals Inc.9.3
- CureVac N.V.11.1
- Arcturus Therapeutics Holdings Inc.7.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Drug Type30.4%
Therapeutic Application25.2%
Delivery Technology20.4%
End User24.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.0
- Europe24.1
- Asia Pacific21.8
- Latin America13.4
- Middle East and Africa8.8
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Moderna Inc. | 88 | 89 | 97 | 82 | 89 | 90 | 89 |
| BioNTech SE | 84 | 72 | 86 | 73 | 75 | 76 | 78 |
| Alnylam Pharmaceuticals Inc. | 62 | 85 | 86 | 72 | 69 | 67 | 74 |
| Ionis Pharmaceuticals Inc. | 57 | 80 | 71 | 63 | 58 | 63 | 65 |
| CureVac N.V. | 69 | 56 | 75 | 57 | 76 | 76 | 68 |
| Arcturus Therapeutics Holdings Inc. | 59 | 54 | 53 | 69 | 64 | 64 | 61 |
| Dicerna Pharmaceuticals | 43 | 62 | 57 | 49 | 61 | 60 | 55 |
| Inc. (a subsidiary of Novo Nordisk) | 56 | 57 | 58 | 53 | 60 | 58 | 57 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Moderna Inc.
- BioNTech SE
- Alnylam Pharmaceuticals Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Moderna Inc. | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| BioNTech SE | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Alnylam Pharmaceuticals Inc. | − | ◐ | ◐ | ◐ | ✓ | ◐ |
| Ionis Pharmaceuticals Inc. | − | ◐ | ◐ | − | ◐ | − |
| CureVac N.V. | ◐ | ◐ | ✓ | ◐ | ✓ | − |
| Arcturus Therapeutics Holdings Inc. | ◐ | ◐ | − | ✓ | ◐ | ◐ |
| Dicerna Pharmaceuticals | − | ◐ | − | − | ◐ | ◐ |
| Inc. (a subsidiary of Novo Nordisk) | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Moderna Inc.89
2BioNTech SE78
3Alnylam Pharmaceuticals Inc.74
4CureVac N.V.68
5Ionis Pharmaceuticals Inc.65
6Arcturus Therapeutics Holdings Inc.61
7Inc. (a subsidiary of Novo Nordisk)57
8Dicerna Pharmaceuticals55
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Moderna Inc.BioNTech SE
Challenger2
Strong scale, closing on the leaders.
Alnylam Pharmaceuticals Inc.CureVac N.V.
Contender3
Focused players with pockets of strength.
Ionis Pharmaceuticals Inc.Arcturus Therapeutics Holdings Inc.Inc. (a subsidiary of Novo Nordisk)
Niche1
Specialists in a single segment or region.
Dicerna Pharmaceuticals
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Drug Type in North America, then scale across RNA Drugs Market — a $124M beachhead inside a $2.09B market.
Beachhead (SOM)$124Mobtainable near-term
Serviceable (SAM)$806Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
mRNA Therapeutics
Best fit — highest urgency & budget in Drug Type.
Economic buyer80 fit
siRNA Therapeutics
Strong fit — clear ROI and a fast path to value.
End user67 fit
Antisense Oligonucleotides (ASOs)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Therapeutic Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Delivery Technology
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel30%
Digital / self-serve18%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Drug Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win RNA Drugs Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified21%
Evaluation12%
Closed-won7%
$15.1KCAC
$86KLTV
5.7:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
RNA Drugs Market is a durable-growth opportunity — $8.17B by 2033, compounding at 9.5%.
TAM · 2025$3.95Btoday
TAM · 2033$8.17Bforecast
CAGR9.5%2027–2033
Cumulative$52.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.17BTotal addressable market
SAM$3.01BServiceable available market
SOM$547MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.5% CAGR
Demand compounds through 2033, outpacing GDP across Drug Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Type moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.17BLarge & growingTAM by 2033 at 9.5% CAGR
$3.01BServiceable nowreachable with today’s model
$547MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.38BBear6.2% CAGR
$8.17BBase9.5% CAGR
$10.5BBull12.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Therapeutic Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
RNA Drugs Market — a $8.34B market by 2033. Plan: grow share from 8.3% to 16.6%.
Market size · 2033$8.34Btotal addressable
Market CAGR6.3%2027–2033
Target share16.6%from 8.3% today
Revenue ambition$1.38Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.3% | 16.6% | Behind |
| Revenue | $671M | $1.38B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 36.3% | 39.0% | On track |
| Customer retention | 89.7% | 95.6% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Drug Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Therapeutic Application capability
A defensible second engine — invest in Therapeutic Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Therapeutic Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $167M capacity & capability investment
- Greenlight bolt-on M&A in Therapeutic Application
- Authorise North America expansion plan
- Fund R&D program for Drug Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the RNA Drugs Market conversation — a $4.61B market you can size, segment and defend in minutes.
Market size · 2033$4.61Btotal opportunity
Growth5.9%CAGR to 2033
Addressable buyers1,170+accounts in scope
Typical ROI4.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Type
Goal Grow share in Drug Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.7×return on cost, year one
< 4 mopayback period
$63K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Moderna Inc.BioNTech SEAlnylam Pharmaceuticals Inc.Ionis Pharmaceuticals Inc.CureVac N.V.Arcturus Therapeutics Holdings Inc.Dicerna PharmaceuticalsInc. (a subsidiary of Novo Nordisk)+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your RNA Drugs Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
RNA Drugs Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Rivanol Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportRenal Cell Carcinoma Drugs Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportRenal Cell Cacinoma Drugs Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportNizatidine Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportNitroglycerin Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportRapamune (Sirolimus) Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportRanolazine Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportRanitidine Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportNasal Spray Flu Vaccines Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportRamipril (CAS 87333-19-5) Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportNasal Drug Delivery Systems Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportNasal Drops Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.